BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the BioAccel Therapeutics conference call, which will include an update on the company's late stage clinical programs and the discussion of financial results for the fourth quarter and full year 2023. At this time, all participants are in listen-only mode. If during the conference call you require operator assistance, please press star zero on your telephone keypad. After the formal remarks will be a question and answer session. If you'd like to register a question, you may press star 1 on your telephone keypad. Just to remind everyone, certain matters discussed in today's conference call and or answers that may be given to questions asked or forward-looking statements subject to risks and uncertainties related to future events and or the future financial or business performance of the company. Actual results could differ materially from those anticipated in those forward-looking statements. Risk factors that may affect future results are detailed in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2023, which can be found at www.bioexhealththerapeutics.com or on www.sec.gov, and which will be updated in its annual report on Form 10-K for the year ended December 31, 2023. As a reminder, today's call is being recorded. Speaking on today's call are Dr. Vimal Mehta, Chief Executive Officer, Dr. Vince O'Neill, Chief of Product Development and Medical Officer, and Richard Steinhardt, Chief Financial Officer. They will be joined in the Q&A session by Dr. Frank Yacob, Chief Scientific Officer, Matt Wiley, Chief Commercial Officer, and Dr. Rob Reisinger, Chief Medical Officer of Neuroscience. It's now my pleasure to turn the call over to Dr. Mehta. Please go ahead. Thank you, operator. Good morning, and thank you for...